Clinical Trial Update: Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 trial comparing once-weekly exenatide to insulin detemir in patients with type 2 diabetes; results were posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Exenatide (once-weekly) (exenatide)
• Insulin detemir (insulin detemir)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2012-12-18